First published case: advanced Alzheimer's reversed in 19 hours after a single psilocybin dose

This is the first published case of an advanced Alzheimer’s patient regaining speech, detailed memory, and bladder control simultaneously within 19 hours.

After a single 5g dose of psilocybin-containing mushrooms, an 80-year-old woman — bedbound, incontinent, and speaking only single syllables for years — woke up roughly 19 hours later talking fluently for hours and recalling long-lost life events.

In the days that followed, dramatic improvements were documented:

• speech restored
• walking regained
• emotional connection returned
• independent dressing
• bladder control restored after five years

Some gains were still present at the one-month follow-up. No approved drug has ever produced anything close.

What the science says

This is not a rumor — it refers to a real, peer-reviewed case report published in Frontiers in Neuroscience on 28 May 2026 by Lago, Cerveira & Simonet, titled “Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration.”

Two honest caveats, because the truth matters more than the headline: it is a single patient, and the improvements were transient — they faded over time. A case report cannot prove that psilocybin caused the recovery. What it does is raise a serious, testable question and point to a body of supporting laboratory and early-clinical research, linked below.

When and where

The treatment was carried out in São Paulo, Brazil, in routine private clinical practice (the Associação Cruz de Ankh) — not a formal experiment or research trial. The mushrooms were the “Enigma” strain, a rare Psilocybe cubensis mutant that grows as a dense, blue-bruising, brain-like cluster. The woman received a 5-gram dose, followed by a smaller 3-gram dose about a month later. The report does not give the exact date of treatment; it was published on 28 May 2026.

Source: original video by Nicolas Hulscher.

Image: a stylized illustration of the “Enigma” strain (a rare Psilocybe cubensis mutant) used in this case.